Co-Diagnostics Invited to Present at Stop TB Partnership Summit in Washington, D.C.

Co-Diagnostics (NASDAQ: CODX) was invited to present its Co-Dx MTB test on the Co-Dx PCR platform at the Stop TB Partnership Summit in Washington, D.C. on April 17, 2026.

Rhea-AI Summary

Co-Diagnostics (NASDAQ: CODX) was invited to present its Co-Dx MTB test on the Co-Dx PCR platform at the Stop TB Partnership Summit in Washington, D.C. on April 17, 2026.

The company will present at a roundtable with U.S. government agencies and private-sector stakeholders. According to the company, the platform aligns with recent WHO guidance on near-point-of-care molecular diagnostics and tongue-swab testing. The Co-Dx PCR platform remains under FDA and other regulatory review and is not yet available for sale.

Argus Apr 16 session

+2.82% close to close Open Argus

Details

News Market Reaction – CODX

In the Apr 16 session, CODX gained 2.82%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement underscores CODX’s strategy of using global TB forums to spotlight its Co-Dx PCR p...

Analysis

This announcement underscores CODX’s strategy of using global TB forums to spotlight its Co-Dx PCR platform and MTB test, which are aligned with recent WHO guidance but remain under regulatory review and not yet for sale. In context of 2025 revenue of $0.6M and a $46.9M net loss, investors may watch how such visibility translates into concrete regulatory milestones, commercialization steps, and updated partnership or JV arrangements.

Key Figures

2025 revenue: $0.6M 2025 operating expenses: $50.6M Intangible impairment: $18.9M +5 more

2025 revenue

$0.6M

Full year 2025 vs $3.9M in 2024

2025 operating expenses

$50.6M

Full year 2025, includes $18.9M impairment

Intangible impairment

$18.9M

Included in 2025 operating expenses

2025 net loss

$46.9M

Full year 2025, or $35.25 per share

Cash & securities

$11.9M

Year-end 2025 balance reported in filings

Equity offerings

$10.8M

Closed equity offerings highlighted in 2025 results

Nasdaq panel monitoring

1 year

Monitoring period through March 9, 2027

52-week range

$1.35–$46.50

Low–high range before this news

Previous Partnership Reports

4 past events · Latest: Apr 02

Same Type 4 events

1. Apr 02

   Saudi JV facility

   24h Move

   -4.9%

   JV CoMira secured Saudi industrial land for a diagnostics manufacturing facility.

2. Feb 05

   India device license

   24h Move

   +0.0%

   CoSara received CDSCO license to manufacture and sell the PCR Pro instrument.

3. Dec 18

   TB course invite

   24h Move

   +5.3%

   CoSara invited to an advanced TB diagnostics course with global health partners.

4. Nov 05

   CoSara SPAC review

   24h Move

   +3.5%

   Company engaged Maxim Group to explore a SPAC or similar listing for CoSara.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

molecular diagnostics, pcr platform, near-point-of-care, tongue swabs, +1 more

5 terms

molecular diagnostics medical

"a molecular diagnostics company with a unique, patented platform"

Molecular diagnostics are laboratory tests that look for specific molecules — such as genes, pieces of DNA or RNA, or proteins — to detect disease, predict risk, or guide treatment choices. For investors, these tests matter because they can change how illnesses are diagnosed and treated, create recurring revenue through specialized tests and companion products, and face clear regulatory and reimbursement pathways that drive commercial value; think of them as reading a biological barcode to inform medical decisions.

pcr platform medical

"the Co-Dx PCR platform* during a roundtable discussion"

A PCR platform is a laboratory system—hardware, reagents and software—used to find and copy tiny amounts of genetic material so they can be detected and measured, like a photocopier that makes a whisper loud enough to hear. Investors care because these platforms drive sales, recurring consumable revenue, regulatory approvals and customer lock‑in in diagnostics and drug development, so adoption and performance directly affect a company’s growth and risk profile.

near-point-of-care medical

"guidance from the World Health Organization related to near-point-of-care molecular diagnostics"

Near-point-of-care describes medical tests or devices placed close to where patients receive care — for example in clinics, urgent care centers, pharmacies, or outpatient suites — rather than in a distant central laboratory or at the bedside. Like having a coffee machine in the office instead of sending everyone to a café, these tools deliver faster results and simpler workflows, which can speed diagnosis, lower costs, and influence adoption, reimbursement, and revenue potential that investors track.

tongue swabs medical

"molecular diagnostics and easy-to-collect tongue swabs for patients"

Tongue swabs are a simple, noninvasive way to collect cells and saliva from the surface of the tongue using a cotton or synthetic swab to detect pathogens, genetic material, or chemical markers. They matter to investors because this low-cost, easy-to-use sampling method can enable large-scale screening, at-home testing and faster clinical studies—like taking a fingerprint instead of drawing blood—potentially lowering costs, widening markets and influencing regulatory and reimbursement dynamics.

fda regulatory

"subject to review by the FDA and/or other regulatory bodies"

The FDA is the U.S. federal agency that evaluates and approves medical drugs, devices, biological therapies and certain foods; think of it as the gatekeeper that decides whether a medical product is safe and effective for patients. For investors, FDA decisions determine whether a company can sell a product, affect expected revenue and introduce regulatory risk, so approvals, rejections or safety warnings can quickly move a company's valuation and stock price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MTB test on Co-Dx PCR platform* to be presented at roundtable with Stop TB Partnership, U.S. Department of State, and global stakeholders

SALT LAKE CITY, April 16, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has been invited to participate in the Stop TB Partnership Summit in Washington, D.C. on April 17, 2026. The Company will present the Co-Dx Mycobacterium tuberculosis ("MTB" or "TB") test on the Co-Dx PCR platform* during a roundtable discussion with U.S. government agencies and other U.S.-based private sector companies.

"We anticipate that the Co-Dx PCR platform, including the Co-Dx MTB test kit, has the potential to play a transformative role in where, how, and how often TB testing occurs, especially following recently-announced guidance from the World Health Organization related to near-point-of-care molecular diagnostics and easy-to-collect tongue swabs," said Dwight Egan, CEO of Co-Diagnostics. "We believe this is a timely opportunity to present the platform to representatives from so many other global stakeholders at this Summit dedicated to stopping TB."

The Stop TB Partnership Summit is being organized to catalyze and engage U.S. private sector companies and innovators directly involved in the global fight against TB, providing a platform to connect with U.S. government agencies and reinforcing initiatives to help build a stronger collective pipeline of TB products, technologies, and partnerships.

The event is expected to highlight opportunities arising from the TB epidemic and identify methods to expand engagement in the global TB response. These efforts are intended to strengthen and broaden relationships between the public and private sectors and the Stop TB Partnership, supporting the development, evaluation and implementation of products aimed at helping end TB.

Last month, the Company shared that the World Health Organization ("WHO") recently released guidance related to near-point-of-care ("NPOC") molecular diagnostics and easy-to-collect tongue swabs for patients who cannot produce sputum samples, and that the Company's testing platform and Co-Dx MTB NPOC test* are already aligned with the WHO guidance.

*The Co-Dx PCR platform (including the PCR Home^®, PCR Pro^®, mobile app, and all associated tests) is subject to review by the FDA and/or other regulatory bodies and is not yet available for sale.

About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) and to identify genetic markers for use in applications other than infectious disease.

Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the potential capabilities, performance, and impact of the Company's Co-Dx PCR platform and MTB test, the anticipated benefits of participation in the Stop TB Partnership Summit, and the potential role of the Company's technologies in addressing global tuberculosis testing needs. These forward-looking statements are based on current expectations, estimates, and projections, as well as management's beliefs and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described herein. Such risks and uncertainties include, but are not limited to, the Company's ability to obtain required regulatory approvals, the timing and success of product development and commercialization efforts, market acceptance of the Company's technologies, changes in global health priorities or funding, and other risks described in the Company's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Forward-looking statements speak only as of the date of this release, and the Company undertakes no obligation to update or revise any such statements, except as required by law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-invited-to-present-at-stop-tb-partnership-summit-in-washington-dc-302744309.html

SOURCE Co-Diagnostics

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What will Co-Diagnostics (CODX) present at the Stop TB Partnership Summit on April 17, 2026?

Co-Diagnostics will present the Co-Dx MTB test on its PCR platform during a roundtable discussion. According to the company, the presentation targets U.S. agencies and private-sector stakeholders to highlight NPOC TB testing alignment with WHO guidance.

How does the Co-Dx MTB test align with WHO guidance mentioned by Co-Diagnostics (CODX)?

The Co-Dx MTB test is described as aligned with WHO guidance on near-point-of-care molecular diagnostics and tongue-swab testing. According to the company, the test and platform already reflect WHO recommendations for patients who cannot produce sputum.

Is the Co-Dx PCR platform available for sale now for Co-Diagnostics (CODX)?

No, the Co-Dx PCR platform is not yet available for sale and remains under regulatory review. According to the company, the PCR Home, PCR Pro, mobile app and associated tests are subject to FDA and other regulatory review.

Who will Co-Diagnostics (CODX) meet with at the Stop TB Partnership Summit roundtable?

Co-Diagnostics will present to U.S. government agencies and other U.S.-based private sector companies at the roundtable. According to the company, global stakeholders and Stop TB Partnership representatives will also participate to discuss TB product development.

What is the intended purpose of Co-Diagnostics' presentation at the April 17, 2026 Stop TB Partnership Summit?

The presentation aims to showcase the Co-Dx platform's potential to expand TB testing access and methods. According to the company, the goal is to engage partners and catalyze collaboration to support TB product development and implementation.